Abstract

Heart failure with preserved ejection fraction in rheumatoid arthritis and the role of interleukin-6 blockade

Author(s): Mohammed Omair, Rashid AlBallaa, Eman Alqurtas & Waleed Al-Habeeb

There is growing evidence on the potential benefits of tocilizumab on the cardiovascular system in Rheumatoid Arthritis (RA) patients. We discuss a case of active RA and refractory Heart Failure with Preserved Ejection Fraction (HFpEF) that has shown dramatic improvement in her articular and cardiac symptoms. This report gives some evidence that tocilizumab could be safely used in RA patients with HFpEF and justify future research on interleukin-6 blockade in heart failure in general.